PMID- 20565778
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1478-7547 (Electronic)
IS  - 1478-7547 (Linking)
VI  - 8
DP  - 2010 Jun 17
TI  - Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids 
      for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 
      Canada.
PG  - 14
LID - 10.1186/1478-7547-8-14 [doi]
AB  - OBJECTIVES: Intravenous immunoglobulin (IVIG) has demonstrated improvement in 
      chronic inflammatory demyelinating polyneuropathy (CIDP) patients in placebo 
      controlled trials. However, IVIG is also much more expensive than alternative 
      treatments such as corticosteroids. The objective of the paper is to evaluate, 
      from a Canadian perspective, the cost-effectiveness of IVIG compared to 
      corticosteroid treatment of CIDP. METHODS: A markov model was used to evaluate 
      the costs and QALYs for IVIG and corticosteroids over 5 years of treatment for 
      CIDP. Patients initially responding to IVIG could remain a responder or relapse 
      every 12 week model cycle. Non-responding IVIG patients were assumed to be 
      switched to corticosteroids. Patients on corticosteroids were at risk of a number 
      of adverse events (fracture, diabetes, glaucoma, cataract, serious infection) in 
      each cycle. RESULTS: Over the 5 year time horizon, the model estimated the 
      incremental costs and QALYs of IVIG treatment compared to corticosteroid 
      treatment to be $124,065 and 0.177 respectively. The incremental cost per QALY 
      gained of IVIG was estimated to be $687,287. The cost per QALY of IVIG was 
      sensitive to the assumptions regarding frequency and dosing of maintenance IVIG. 
      CONCLUSIONS: Based on common willingness to pay thresholds, IVIG would not be 
      perceived as a cost effective treatment for CIDP.
FAU - Blackhouse, Gord
AU  - Blackhouse G
AD  - PATH Research Institute, McMaster University, Hamilton, Ontario, Canada. 
      blackhou@mcmaster.ca.
FAU - Gaebel, Kathryn
AU  - Gaebel K
FAU - Xie, Feng
AU  - Xie F
FAU - Campbell, Kaitryn
AU  - Campbell K
FAU - Assasi, Nazila
AU  - Assasi N
FAU - Tarride, Jean-Eric
AU  - Tarride JE
FAU - O'Reilly, Daria
AU  - O'Reilly D
FAU - Chalk, Colin
AU  - Chalk C
FAU - Levine, Mitchell
AU  - Levine M
FAU - Goeree, Ron
AU  - Goeree R
LA  - eng
PT  - Journal Article
DEP - 20100617
PL  - England
TA  - Cost Eff Resour Alloc
JT  - Cost effectiveness and resource allocation : C/E
JID - 101170476
PMC - PMC2903512
EDAT- 2010/06/23 06:00
MHDA- 2010/06/23 06:01
PMCR- 2010/06/17
CRDT- 2010/06/23 06:00
PHST- 2009/11/27 00:00 [received]
PHST- 2010/06/17 00:00 [accepted]
PHST- 2010/06/23 06:00 [entrez]
PHST- 2010/06/23 06:00 [pubmed]
PHST- 2010/06/23 06:01 [medline]
PHST- 2010/06/17 00:00 [pmc-release]
AID - 1478-7547-8-14 [pii]
AID - 10.1186/1478-7547-8-14 [doi]
PST - epublish
SO  - Cost Eff Resour Alloc. 2010 Jun 17;8:14. doi: 10.1186/1478-7547-8-14.